We're raising our price target on Eli Lilly as the obesity-drug boom rolls on

Eli Lilly reported Q3 revenue of $24.4B, up 39% year over year and above the $22.6B consensus, while adjusted EPS of $7.48 beat the $6.26 estimate; shares rose more than 6% to a record near $1,370. Mounjaro revenue increased 65% to $10.7B and Zepbound sales rose 49% to $5.35B, offsetting lower realized prices, though Foundayo revenue of $184M missed the $229M consensus. Lilly raised 2026 revenue guidance to $91B-$92B from $85B-$87B and performance margin guidance to 52%-52.5%, but lowered EPS guidance to $35-$36 from $35.50-$36.50; the article's author raised the price target to $1,500 from $1,300 while reiterating a rating of 2 and advising a pullback before adding.

Analysis

The key debate is shifting from demand validation to the economics and durability of converting new patients into profit. Recent volume growth appears to absorb lower realized prices, but China reimbursement and U.S. access programs may make that trade-off more visible as the patient base scales. The Medicare pilot is a demand catalyst now and a policy/renewal risk later: prescribing through the program does not yet establish durable, unsubsidized demand or economics after the pilot. Watch net price, patient persistence, and contribution to operating cash flow—not prescription share alone.

The quarterly beat strengthens the near-term earnings floor, but the raised revenue and operating-profit outlook alongside lower EPS guidance warrants a reconciliation of acquisition-related charges and other below-operating-line items. It is not evidence by itself of deteriorating core profitability, but it may limit how much investors reward revenue beats. Foundayo’s below-expectation launch is a modest warning against treating oral adoption as automatic; the injectable franchise remains the nearer-term earnings engine. Pipeline assets may support the longer-term multiple, but should not be valued as realized growth before clinical and regulatory proof.

Near term, momentum and estimate revisions favor the shares, yet a record high after a sharp advance raises the bar for another positive surprise. Over 1–3 months, the R&D investor day and detailed next-year guidance are catalysts; over 6–18 months, payer access, realized prices, persistence, capacity, and oral-product competition determine whether volume growth translates into earnings growth. The contrarian risk is that investors extrapolate broad eligibility into profitable penetration. A price-volume mix deterioration or weaker persistence could reverse that narrative.

Key Decisions for Investors

• Do not chase the post-results gap. For existing exposure, hold a core position but consider trimming into further sharp strength; add only after a pullback or after guidance confirms that volume growth is translating into cash earnings.
• Use the next guidance update and investor day as event checkpoints, not as standalone buy signals. Verify the EPS-to-operating-profit bridge, acquisition-related charges, net realized pricing by geography, and whether the Medicare pilot’s economics persist beyond its initial term.
• Treat a relative long LLY / short Novo Nordisk as a watchlist pair rather than an immediate trade: establish only if subsequent prescription and launch data show Lilly sustaining share gains without disproportionate net-price or margin erosion. The thesis is falsified by a sustained reversal in relative share or weaker Lilly price-volume mix.
• Reduce bullish conviction if Lilly lowers forward operating-profit or cash-flow expectations, if patient persistence weakens, or if lower realized prices outpace volume gains. Conversely, sustained margin performance alongside continued volume growth would validate the earnings durability thesis.